Company Overview
Indaptus Therapeutics, Inc. operates as a clinical biotechnology company dedicated to the development of various anti-cancer and anti-viral immunotherapy products, with its primary focus currently centered on Decoy20 for single agent activity and combination therapy-based durable responses. The company functions within the Healthcare sector, specifically under the Biotechnology industry, which characterizes its business model as relying on the discovery and clinical advancement of novel therapeutic agents rather than traditional product sales. As of the latest data, the company maintains a market capitalization of $3.99M and employs 5 individuals to drive its research and development initiatives. These financial metrics indicate that Indaptus is a micro-cap entity with minimal revenue generation, positioning it as a high-risk, early-stage development company where value is derived entirely from intellectual property potential and future clinical trial outcomes rather than current operational cash flows or established market share.
Financial Health
The company reports a net income of $-20,848,916 for the trailing twelve months, while its free cash flow stands at $-8,159,969, reflecting a significant gap between top-line revenue and bottom-line profitability that reveals a heavy cost structure driven by research expenses and clinical trial costs. Although revenue figures are not available for the trailing twelve months, the substantial negative net income and free cash flow suggest that the company is burning cash to advance its clinical pipeline, a common characteristic for biotechnology firms in the development phase. All three key margin metrics—Gross Margin, Operating Margin, and Profit Margin—are reported at 0.0%, indicating that the company has not yet achieved commercial sales sufficient to generate positive gross profitability or operating leverage. Despite these losses, the company holds $8.51M in cash reserves against N/A in debt, creating a liquidity position that allows for continued operations without immediate refinancing needs. The absence of a reported debt-to-equity ratio and N/A for total debt suggests the company is unleveraged, relying on equity financing or cash reserves to fund its operations. The current ratio of 1.51 indicates that the company possesses 1.51 times the assets relative to its short-term liabilities, providing a moderate buffer for meeting obligations over the next year. Furthermore, the Return on Equity is -587.6% and the Return on Assets is -148.9%, metrics that reveal management is currently operating without the ability to generate positive returns on shareholder capital or asset base, a typical but critical risk factor for pre-revenue biotech entities.
Valuation Assessment
The trailing P/E ratio is not available due to the absence of positive net income, while the forward P/E is listed as -1.28, implying that the market is currently pricing in expected future earnings losses or that the valuation model relies on alternative metrics for this stage of development. The price-to-book ratio is 1.23, indicating that the market values the company at a slight premium of 23% over its book value, which may reflect the intangible value of its clinical candidates like Decoy20 despite the lack of commercial revenue. Alternative valuation metrics include a price-to-sales ratio that is not available and an EV/EBITDA of 0.23, suggesting that the enterprise value is extremely low relative to its negative earnings, a valuation often seen in distressed or pre-commercial biotechnology firms. The stock has exhibited significant volatility over the past year, trading between a 52-week low of $1.52 and a 52-week high of $21.84, placing the current trading range in a context of extreme price discovery typical for small-cap biotech stocks. The beta value is 1.00, which indicates that the stock's price volatility moves in tandem with the broader market, lacking the typical defensive or aggressive deviation often seen in healthcare sectors.
Growth & Income
The company reports N/A for revenue growth year-over-year and N/A for earnings growth year-over-year, meaning that historical growth rates cannot be calculated and earnings are not growing faster or slower than revenue in a measurable sense due to the lack of a commercial base. As a non-dividend payer, Indaptus Therapeutics does not distribute a dividend yield or maintain a payout ratio, instead retaining all generated earnings or cash reserves to reinvest directly into the growth of its clinical pipeline and research activities. The overall growth and income profile is characterized by zero current income distribution and undefined historical growth rates, relying entirely on the potential for future clinical successes to drive capital appreciation rather than providing current yield or consistent earnings expansion.